The Drug Science Scientific Committee regularly publishes world-leading research in high-impact peer reviewed journals.

Authors: Tom P Freeman, Chandni Hindocha, Gianluca Baio, Natacha D C Shaban, Emily M Thomas, Danica Astbury, Abigail M Freeman, Rachel Lees, Sam Craft, Paul D Morrison, Michael A P Bloomfield, Dominic O'Ryan, Jane Kinghorn, Celia J A Morgan, Ali Mofeez, H Valerie Curran Published: July 28, 2020A…

Authors: Ben Sessa, Chloe Sakal, Steve O’Brien and David Nutt Published: July 15, 2019Read the full paper here (open access) We present the preliminary data in the Bristol-Imperial MDMA-for-Alcoholism (BIMA) study, an ongoing open-label safety and tolerability proof of concept study exploring the potential role for 3,4-methylenedioxymethamphetamine (MDMA)-assisted…

Authors: Ole Rogeberg, Daniel Bergsvik, Lawrence D. Phillips, Jan van Amsterdam, Niamh Eastwood, Graeme Henderson, Micheal Lynskey, Fiona Measham, Rhys Ponton, Steve Rolles, Anne Katrin Schlag, Polly Taylor, and David Nutt Published: February 17, 2018In collaboration with drug experts in Norway and the UK, multi-criteria decision analysis has…

A review and analysis of the ethical considerations in off-label ketamine use for severe, treatment-resistant depression. The review concludes that further restrictions around ketamine are not neccesary and provides a set of recomendations for oversight bodies that would support safe, effective, and ethical use. Read it here

Authors: Polly Taylor, David Nutt, Val Curran, Rudi Fortson, and Graeme Henderson Published: March 11, 2016A letter to The Lancet endorsing the WHO Expert Committee on Drug Dependence's conclusion that concerns over recreational ketamine abuse in no way outweigh ketamine's role as a life-saving anasthetic and essential medicine.For…